drugset / Trial / NCT01219192
Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line Gemcitabine treatment failure.
Timeline
- Start
- 2010-08
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M2ES | Protein / enzyme biologic | 15 mg | Intravenous |
| Subject | M2ES | Protein / enzyme biologic | 30 mg | Intravenous |
| Subject | M2ES | Protein / enzyme biologic | 45 mg | Intravenous |
| Subject | M2ES | Protein / enzyme biologic | 60 mg | Intravenous |